# A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

> **NCT04787289** · PHASE2 · RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 244 (estimated)

## Conditions studied

- Ovarian Cancer
- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04787289
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-10
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787289, "A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04787289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*